CStone Pharmaceuticals
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biopharma leader in China developing innovative oncology and immunology therapies.
OncologyImmunology
Technology Platform
Focused on immuno-oncology and molecularly targeted therapies, including checkpoint inhibitors and small molecule inhibitors.
Opportunities
Significant growth potential in the large Chinese oncology market and through ex-Asia partnerships for its clinical-stage assets.
Risk Factors
Commercial execution risks and pricing pressure in the highly competitive oncology segment in China.
Competitive Landscape
Faces strong competition in the crowded Chinese PD-1/PD-L1 inhibitor market from companies like Junshi Biosciences and Innovent, as well as global giants.